EUG..............................................................................................................................................................12

Werkgroep module 5

MD-K 5.1 Bloedverlies in de eerste helft van de zwangerschap..............................................5 Oorzaken van bloedverlies <16 wk......................................................................................................5 Oorzaken van bloedverlies 16-24 wk.................................................................................................6 Miskraam (spontane abortus)................................................................................................................6 EUG..............................................................................................................................................................12 Mola hydatidosa.......................................................................................................................................15 Niet gynaecologische oorzaken blv...................................................................................................16 Gynaecologische oorzaken blv............................................................................................................16 Werkcollege.......................................................................................................................................17 MD-K 5.2 afwijkingen placenta vliezen en navelstreng...........................................................21 Placenta locaties......................................................................................................................................21 Afwijkingen placenta..............................................................................................................................24 Afwijkingen vliezen.................................................................................................................................26 Afwijkingen navelstreng.......................................................................................................................27 Werkcollege.......................................................................................................................................27 MD-K 5.3 Bloedverlies in het 2e en 3e trimester.......................................................................28 Obstetrische oorzaken van bloedverlies >24 weken...................................................................28 ● Placenta praevia...................................................................................................................................28 ● Abruptio placentae..............................................................................................................................29 ● (Gescheurde) vasa praevia................................................................................................................32 ● Dreigende vroeggeboorte.................................................................................................................33 ● Randvenebloeding..............................................................................................................................33 ● Placenta circumvallata.......................................................................................................................33 ● Uteruslitteken........................................................................................................................................34 Werkcollege.......................................................................................................................................36 MD-K 5.4 Oligo en polyhydramnion..............................................................................................38 Vruchtwater...............................................................................................................................................38 Embryologie nieren.................................................................................................................................39 ● Polyhydramnion...................................................................................................................................42 Polyhydramnion door infectie..............................................................................................................43 Polyhydramnion door rhesusincompabiliteit..................................................................................43 ● Oligohydramnion.................................................................................................................................44 ● Potter sequentie......................................................................................................................................1 ● Oligohydramion door TTST twin to twin transfusion syndrome............................................1 ● Oligohydramnion door ACE remmers of NSAID’s.......................................................................1 1 / 4

Werkcollege..........................................................................................................................................1 MD-K 5.5 Caput beweeglijk op bekkeningang..............................................................................1 Prevalentie....................................................................................................................................................1 Oorzaak..........................................................................................................................................................1 Diagnostiek..................................................................................................................................................1 Gevolgen.......................................................................................................................................................1 Beleid.............................................................................................................................................................1 MD-K 5.6 Schildklieraandoeningen.................................................................................................1 Fysiologie schildklier.................................................................................................................................1 Hyperthyroïdie............................................................................................................................................1 Hypothyroidie..............................................................................................................................................1 Fysiologie schildklier zwangerschap...................................................................................................1 Schildklier aandoeningen en zwanger................................................................................................1 Hyperthyroidie in de zwangerschap....................................................................................................1 Hypothyreoïdie en zwangerschap........................................................................................................1 Postpartum thyroiditis..............................................................................................................................1 Werkcollege..........................................................................................................................................1 MD-K 5.7 Hemoglobinopathieën......................................................................................................1 Erytropoëse..................................................................................................................................................1 Sikkelcelanemie..........................................................................................................................................1 Sikkelcelanemie verloskunde.................................................................................................................1 Thalassemie.................................................................................................................................................1 Laboratoriumonderzoek anemie............................................................................................................1 Screening HbP’s.........................................................................................................................................1 Werkcollege..........................................................................................................................................1 MD-K 5.8 Tractus uropoeticus...........................................................................................................1 Anatomie TU................................................................................................................................................1 Urineproductie.............................................................................................................................................1 Glomerulaire filtratie.................................................................................................................................1 Glomerulaire filtratie druk.......................................................................................................................1 Tubulaire reabsorbtie................................................................................................................................1 Reabsorbtieproces.....................................................................................................................................1 Tubulaire secretie.......................................................................................................................................1 Na+ en waterhuishouding.......................................................................................................................1 RAAS systeem............................................................................................................................................1 Atriaal natriuretische peptide.................................................................................................................1 Osmoregulatie: regulatie van water....................................................................................................1 Regulatie van calcium...............................................................................................................................1 2 / 4

Zuur base evenwicht.................................................................................................................................1 Endocriene functies...................................................................................................................................1 Werkcollege.................................................................................................................................................1 MD-K 5.9 Aandoeningen tractus uropoeticus...............................................................................1 Hydronefrose...............................................................................................................................................1 Nierstuwing..................................................................................................................................................1 UWI.................................................................................................................................................................1 Nierstenen....................................................................................................................................................1 Urine retentie/ retentieblaas...................................................................................................................1 Urine incontinentie.....................................................................................................................................1 Nefrotisch syndroom.................................................................................................................................1 Werkcollege..........................................................................................................................................1 MD-K 5.10 Tensieregulatie................................................................................................................1 Tensieregulatie............................................................................................................................................1 Zenuwstelsel en bloedvaten..................................................................................................................1 RAAS systeem............................................................................................................................................1 MD-K 5.11 Hypertensieve aandoeningen.......................................................................................1 Pathofysiologie...........................................................................................................................................1 Screening......................................................................................................................................................1 Preventie.......................................................................................................................................................1 Diagnostiek..................................................................................................................................................1 Monitoring....................................................................................................................................................1 Behandeling.................................................................................................................................................1 Postpartum en toekomst.........................................................................................................................1 Werkcollege..........................................................................................................................................1 MD-K 5.12 Hemostase........................................................................................................................1 Bloeding........................................................................................................................................................1 Hemostase...................................................................................................................................................1 Cascades.......................................................................................................................................................1 Antistolling...................................................................................................................................................1 Vitamine K....................................................................................................................................................1 Veranderingen zwangerschap...............................................................................................................1 MD-K 5.13 Bloedgroepimmunisatie................................................................................................1 Bloedgroepsystemen................................................................................................................................1 Bloedgroep antagonisme........................................................................................................................1 Gevolgen IEA...............................................................................................................................................1 Diagnostiek..................................................................................................................................................1 Behandeling.................................................................................................................................................1 3 / 4

Screening......................................................................................................................................................1 Preventie.......................................................................................................................................................1 Trombocytenimmunisatie........................................................................................................................1 Werkcollege..........................................................................................................................................1 MD-K 5.14 Neonatale problematiek................................................................................................1 Enterohepatische kringloop....................................................................................................................1 Neonatale enterohepatische kringloop...............................................................................................1 Bilirubine en icterus...................................................................................................................................1 Hyperbilirubinemie....................................................................................................................................1 Pathologische icterus................................................................................................................................1 Polycytemie..................................................................................................................................................1 MD-K 5.15 Psychologie.......................................................................................................................1 MD-K 5.16 Seksualiteit.......................................................................................................................1 Seksuele disfuncties..................................................................................................................................1 Werkcollege..........................................................................................................................................1

• / 4